ESMO 2023 Lung Cancer Highlights – Keynote 671 | ALINA | TropionLung01 | Oncology Brothers

In discussion with Dr. Joshua Reuss, covering the ESMO 2023 Lung Cancer Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Reuss: - Keynote 671 – perioperative approach in non-small cell lung cancer with pembrolizumab and cisplatin based chemo combination, with positive OS data - ALINA – resectable non-small cell lung cancer pts with ALK positive disease, Alectinib will be the new standard of care given incredible DFS - TropionLung 01 – Dato-DXd in 2nd line non-small cell lung cancer reports slightly greater PFS when compared to docetaxel #ESMO #PrecisionMedicine #LungCancer #2023 #cancer #oncology #oncbrothers